If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  AUA MEETING: Study Shows Men With Impotence Satisfied With Invicorp NAPA, CA -- June 3, 1998 -- Data from a six-month, multi-site, placebo-controlled clinical study of Senetek PLC’s Invicorp™, an erectile dysfunction therapy, shows the drug to be a very effective treatment with a remarkable low adverse event profile. The study results were presented by principal investigator Dr. Geoffrey Hackett of the Erectile Dysfunction Clinic, Good Hope Hospital, Sutton Coldfield, England, at the 93rd annual meeting of the American Urological Association, in San Diego, CA. Of 540 patients (mean age 58 years), 83 percent responded to treatment with Invicorp with an erection suitable for sexual intercourse (grade 3 - on a scale of 0-3). Of particular note, 327 of these patients had withdrawn from previous treatment with alternative ED pharmacotherapies. Furthermore, only 12.5 percent of injections responded to placebo. Of the 540 patients, 86 percent of patients were satisfied or very satisfied with the medication and 95 percent were satisfied with the autoinjector delivery system. In addition, 83 percent of patients and 77 percent of their partners recorded that the quality of their lives had improved during the study period. Mild and transient flushing was the only commonly recorded adverse event (32.5 percent of injections given). There were no serious adverse events related to the test medication and no reports of post-injection penile pain. Invicorp, an autoinjectable formulation of vasoactive intestinal polypeptide (VIP), in combination with the adrenergic drug phentolamine mesylate (PMS) and sexual stimulation, provides an effective therapy for ED patients that is essentially free of troublesome side effects and cumbersome delivery methods. More information on: Invicorp and Senetek PLC.
|
